Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
CNS Drugs, vol. 36, pp. 819–858
Abstract
Cognitive impairments associated with schizophrenia (CIAS) represent a central element of the symptomatology of this severe mental disorder. CIAS substantially determine the disease prognosis and hardly, if at all, respond to treatment with currently available antipsychotics. Remarkably, all drugs presently approved for the treatment of schizophrenia are, to varying degrees, dopamine D2/D3 receptor blockers. In turn, rapidly growing evidence suggests the immense significance of systems other than the dopaminergic system in the genesis of CIAS. Accordingly, current efforts addressing the unmet needs of patients with schizophrenia are primarily based on interventions in other non-dopaminergic systems. In this review article, we provide a brief overview of the available evidence on the importance of specific systems in the development of CIAS. In addition, we describe the promising targets for the development of new drugs that have been used so far. In doing so, we present the most important candidates that have been investigated in the field of the specific systems in recent years and present a summary of the results available at the time of drafting this review (May 2022), as well as the currently ongoing studies.
Authors 2
-
RWTH Aachen University · Forschungszentrum Jülich
Affiliation as printed
Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany. tveselinovic@ukaachen.de
Institute of Neuroscience and Medicine 4, INM-4, Forschungszentrum Jülich, Jülich, Germany. tveselinovic@ukaachen.de
Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany
-
RWTH Aachen University · Forschungszentrum Jülich · Jülich Aachen Research Alliance
Affiliation as printed
Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany
Institute of Neuroscience and Medicine 4, INM-4, Forschungszentrum Jülich, Jülich, Germany
JARA-BRAIN, Aachen, Germany
Cited by 28 stored of 28
No patents citing this paper on Lens.org (checked 2026-10-06).